AQR Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-78,988
| Closed | -$240K | – | 3226 |
|
|
2024
Q4 | $240K | Sell |
78,988
-20,199
| -20% | -$88K | ﹤0.01% | 2599 |
|
|
2024
Q3 | $515K | Sell |
99,187
-101,893
| -51% | -$506K | ﹤0.01% | 2160 |
|
|
2024
Q2 | $517K | Buy |
201,080
+170,960
| +568% | +$584K | ﹤0.01% | 2040 |
|
|
2024
Q1 | $148K | Buy |
+30,120
| New | +$178K | ﹤0.01% | 2301 |
|
|
2023
Q3 | – | Sell |
-13,483
| Closed | -$341K | – | 2398 |
|
|
2023
Q2 | $341K | Sell |
13,483
-717
| -5% | -$22.3K | ﹤0.01% | 1900 |
|
|
2023
Q1 | $457K | Buy |
+14,200
| New | +$443K | ﹤0.01% | 1810 |
|
|
2021
Q4 | – | Sell |
-9,691
| Closed | -$270K | – | 2297 |
|
|
2021
Q3 | $270K | Hold |
9,691
| – | – | ﹤0.01% | 2063 |
|
|
2021
Q2 | $287K | Sell |
9,691
-6,517
| -40% | -$188K | ﹤0.01% | 2055 |
|
|
2021
Q1 | $453K | Sell |
16,208
-1,386
| -8% | -$38.3K | ﹤0.01% | 1872 |
|
|
2020
Q4 | $499K | Sell |
17,594
-2,547
| -13% | -$66K | ﹤0.01% | 1790 |
|
|
2020
Q3 | $506K | Buy |
20,141
+6,838
| +51% | +$179K | ﹤0.01% | 1720 |
|
|
2020
Q2 | $325K | Buy |
+13,303
| New | +$263K | ﹤0.01% | 1873 |
|
|
2018
Q4 | – | Sell |
-8,086
| Closed | -$201K | – | 2297 |
|
|
2018
Q3 | $201K | Sell |
8,086
-5,163
| -39% | -$140K | ﹤0.01% | 2194 |
|
|
2018
Q2 | $364K | Buy |
13,249
+39
| +0.3% | +$1.17K | ﹤0.01% | 2076 |
|
|
2018
Q1 | $407K | Buy |
13,210
+356
| +3% | +$11.5K | ﹤0.01% | 1970 |
|
|
2017
Q4 | $460K | Buy |
12,854
+2,463
| +24% | +$70.7K | ﹤0.01% | 1941 |
|
|
2017
Q3 | $286K | Buy |
+10,391
| New | +$252K | ﹤0.01% | 2092 |
|
|
2016
Q3 | – | Sell |
-12,073
| Closed | -$164K | – | 2303 |
|
|
2016
Q2 | $164K | Sell |
12,073
-3,114
| -21% | -$55.1K | ﹤0.01% | 2127 |
|
|
2016
Q1 | $265K | Buy |
15,187
+2,666
| +21% | +$54.3K | ﹤0.01% | 2037 |
|
|
2015
Q4 | $428K | Buy |
+12,521
| New | +$434K | ﹤0.01% | 1930 |
|
Other funds holding RVNC
AQR Capital Management's RVNC Position: Q1 2025 in Review
AQR Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 78,988 shares — an estimated $240K sold.
AQR Capital Management first reported a position in RVNC in Q4 2015 and held it in 20 quarters. The position peaked at $517K in Q2 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- AQR Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- AQR Capital Management sold 78,988 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $240K.
- AQR Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 20 quarters.
- AQR Capital Management's Revance Therapeutics, Inc. position peaked at $517K in Q2 2024.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on AQR Capital Management's 13F filing for Q1 2025, filed 15 May 2025.